New combo aims to control blood cancer, offering hope for treatment breaks
NCT ID NCT04458610
Summary
This study is testing a combination of two drugs, zanubrutinib and rituximab, for people newly diagnosed with a type of blood cancer called chronic lymphocytic leukemia (CLL). The main goal is to see if this treatment can control the cancer well enough that patients can safely stop taking the drugs for at least six months without the disease getting worse. Researchers will also study how long these treatment breaks last and if the same drugs can work again if the cancer returns.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.